Denovo Biomarkers, ALS-ETF Partner on ALS Drug Development Efforts | GenomeWeb

NEW YORK (GenomeWeb News) – The ALS Emergency Treatment Fund and Denovo Biomarkers today announced a partnership to evaluate Denovo's technology to identify patients who may best respond to amyotrophic lateral sclerosis drugs being studied.

The partnership will use Denovo's pharmacogenomic technology in order to identify biomarkers from biological samples from expanded access programs sponsored by ALS-ETF. Biomarkers which can be correlated with patient response to treatments may then be used to identify patient subsets for subsequent trials, the partners said.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

HHS Secretary Tom Price says the NIH budget contains unneeded expenses that can be trimmed, Stat News reports.

The chair of the House science committee says the journal Science is not objective, the Huffington Post reports.

In Nature this week: glioma GWAS uncovers new risk loci, and more.

Ivanka Trump and Secretary of Education Betsy DeVos call on girls to pursue STEM careers, the Associated Press reports.